The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.
 
Karen Kelly
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; G1 Therapeutics; Genentech/Roche; Janssen; Lilly; Regeneron
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Lycera (Inst); Novartis (Inst); Regeneron (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Regeneron
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst)
 
Devalingam Mahalingam
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Genentech
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Genentech
Research Funding - Merck
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Ignyta; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; Lycera; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Christina Wu
Honoraria - BioTheranostics
Research Funding - Amgen; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Vaccinex (Inst)
 
Laura Carter
Employment - Lycera
Stock and Other Ownership Interests - Lycera
 
Xiao Hu
Employment - Lycera
Stock and Other Ownership Interests - Lycera
 
Garry Alan Weems
Employment - Lycera
Stock and Other Ownership Interests - Lycera
 
H. Jeffrey Wilkins
Employment - Lycera
Stock and Other Ownership Interests - Lycera
 
Linda R. Duska
Consulting or Advisory Role - Advance Medical; British Journal of Obstetrics and Gynecology; ClearView Healthcare Partners; Merck; Parexel; UpToDate
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
Other Relationship - Genentech; Merck